New highly potent GABA uptake inhibitors selective for GAT-1 and GAT-3 derived from (R)- and (S)-proline and homologous pyrrolidine-2-alkanoic acids
摘要:
We synthesized proline and pyrrolidine-2-alkanoic acid derivatives in their enantiomerically pure form and evaluated them for their affinity to the GABA transport proteins GAT-1 and GAT-3. Among the compounds presented herein, (R)-pyrrolidine-2-acetic acid (R)-4d substituted with a 2- [tris(4-methoxyphenyl)methoxy] ethyl residue at the nitrogen atom showed the highest affinity at GAT-3 (IC50 = 3.1 mu M) comparable with the well-known GAT-3 blocker (S)-SNAP-5114. Compound (R)-4d displayed excellent subtype selectivity for GAT-3 (GAT-3:GAT-1 = 20:1). (S)-2-pyrrolidineacetic acid derivatives (S)-4b provided with a 4,4-diphenylbut-3-en-1-yl moiety and (S)-4c substituted with a 4,4-[di(3-methylthiophen-2-yl)]phenylbut-3-en-l-yl residue at the nitrogen atom exhibited IC50 values of 0.396 mu M and 0.343 mu M at the GAT-1 protein, respectively. (c) 2006 Elsevier SAS. All rights reserved.
[EN] SUBSTITUTED 4-(1-PYRROLIDINYL)PYRIMIDINE COMPOUNDS AS DIMERIZATION INHIBITORS OF NEURONAL NITRIC OXIDE SYNTHASE [FR] COMPOSÉS DE 4-(1-PYRROLIDINYL)PYRIMIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA DIMÉRISATION DE L'OXYDE NITRIQUE SYNTHASE NEURONALE
N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor Xa
申请人:——
公开号:US20030092698A1
公开(公告)日:2003-05-15
This invention is directed to N-acylpyrrolidin-2-ylalkylbenzamidine derivatives which useful for inhibiting the activity of Factor Xa, by contacting said derivatives with a composition containing Factor Xa. The present invention is also directed to compositions containing said derivatives, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.
The present invention provides PLK1 inhibitor compounds of formula I:
Useful in the treatment or control of cell proliferative disorders, particularly oncological disorders. These compounds and formulations containing such compounds may be useful in the treatment or control of solid tumors, such as, for example, breast, colon, lung and prostate tumors and other oncological diseases such as non-Hodgkin's lymphomas.
[EN] POLO-LIKE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE DE TYPE POLO
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2009067547A1
公开(公告)日:2009-05-28
Compounds of the following formula are provided for use with kinases, wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
Isolation of Pandamarilactonine-H from the Roots of <i>Pandanus amaryllifolius</i> and Synthesis of <i>epi</i>-Pandamarilactonine-H
作者:Mario A. Tan、Mariko Kitajima、Noriyuki Kogure、Maribel G. Nonato、Hiromitsu Takayama
DOI:10.1021/np1003998
日期:2010.8.27
e function, was isolated from the roots of Pandanus amaryllifolius. Eleven known alkaloids were also isolated. Unambiguous assignment of the structure of 1a, including the absolute configuration, was accomplished by spectroscopic analysis and totalsynthesis of itsenantiomer.
Compounds of the following formula are provided for use with kinases:
wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.